Manufacturer Shire has named BioCare as the exclusive, national authorized distributor for CEPROTIN, a Protein C concentrate replacement therapy. It is indicated for the prevention and treatment of venous thrombosis and purpura fulminans for pediatric and adult patients.
Linda Matthews, president of BioCare, said, “We appreciate Shire’s continued confidence in the many capabilities of our organization. We are excited to be an integral part of helping to treat this very rare condition.”
Ceprotin is offered in single-use vials that are available in 500 IU and 1000 IU nominal strengths and is for intravenous injection after reconstitution.
For more information about the efficacy and safety of Ceprotin, visit Ceprotin.
For more information on Shire and its commitment to the patient community, visit Shire.